Acer Therapeutics Inc. was a pharmaceutical company dedicated to the acquisition, development, and commercialization of therapies for serious rare and ultra-rare diseases with significant unmet medical needs. Their pipeline included candidates for conditions such as Urea Cycle Disorders (UCDs), Maple Syrup Urine Disease (MSUD), and Vascular Ehlers-Danlos Syndrome (vEDS). In 2023, Acer Therapeutics was acquired by Zevra Therapeutics, Inc. Acer's key programs, such as OLPRUVA™ (sodium phenylbutyrate) for UCDs, are now part of Zevra's portfolio.
Served as the primary corporate office for executive leadership, research and development program management, clinical operations oversight, and administrative functions for Acer Therapeutics before its acquisition.
The headquarters was likely a modern office space within a business center, designed to facilitate collaboration and manage pharmaceutical development programs. Specific architectural highlights are not widely publicized.
As a company focused on rare diseases, the work culture likely emphasized scientific rigor, patient-centricity, innovation, and a sense of urgency in addressing unmet medical needs. Collaboration among scientific, clinical, and regulatory teams would have been crucial.
The Newton headquarters was central to Acer's strategic decision-making, clinical trial management, and efforts to bring new therapies for rare diseases to market. It represented the core of their operational and scientific endeavors.
Prior to its acquisition by Zevra Therapeutics, Acer Therapeutics Inc. was primarily focused on the United States market for its drug development and commercialization activities. Clinical trials for its product candidates may have involved sites in multiple countries to ensure diverse patient populations and meet regulatory requirements, but its core operational presence and commercial strategy were U.S.-centric.
One Gateway Center, Suite 351
Newton
MA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Acer Therapeutics Inc.' leadership includes:
Acer Therapeutics Inc. has been backed by several prominent investors over the years, including:
The most significant executive changes at Acer Therapeutics Inc. in the last 12-18 months are related to its acquisition by Zevra Therapeutics in mid-2023. This led to the transition or departure of Acer's standalone executive team as operations were integrated.
Discover the tools Acer Therapeutics Inc. uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition, Acer Therapeutics Inc. likely used common corporate email formats. A common pattern for companies of its size is [first_initial][last]@[companydomain].com or [first].[last]@[companydomain].com.
[first_initial][last]@acertherapeutics.com
Format
jsmith@acertherapeutics.com
Example
75%
Success rate
Zevra Therapeutics • August 21, 2023
Zevra Therapeutics, Inc. announced the completion of its acquisition of Acer Therapeutics Inc. This acquisition brings Acer's lead product candidate, OLPRUVA™ (sodium phenylbutyrate), for Urea Cycle Disorders (UCDs) into Zevra's portfolio....more
GlobeNewswire • May 31, 2023
Zevra Therapeutics and Acer Therapeutics announced they entered into a definitive merger agreement under which Zevra would acquire Acer. The deal aimed to strengthen Zevra's rare disease portfolio....more
Acer Therapeutics Inc. • January 27, 2023
Acer Therapeutics announced that the U.S. Food and Drug Administration (FDA) approved OLPRUVA™ for the treatment of certain UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS)....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Acer Therapeutics Inc., are just a search away.